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2-hydroxypropyl-β-cyclodextrin for acute liver disease in infants with
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Yumirle P. Turmelle a, Sakil S. Kulkarni a, Xuntian Jiang a, Geetika Khanna a, Marwan Shinawi a,
Forbes D. Porter b, Daniel S. Ory a, F. Sessions Cole a, Patricia I. Dickson a, *
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Introduction: Niemann-Pick C (NPC) is an autosomal recessive disease due to defective NPC1 or NPC2 proteins
resulting in endo-lysosomal storage of unesterified cholesterol in the central nervous system and liver. Acute liver
disease in the newborn period may be self-limited or fatal. 2-hydroxypropyl-β-cyclodextrin (2HPBCD) is a
cholesterol-binding agent that reduces lysosomal cholesterol storage. We have enrolled 3 infants 0–6 months old
with direct hyperbilirubinemia due to NPC1 or NPC2 liver disease in a Phase I/II open label clinical trial of
intravenous 2HPBCD.
Methods: Infants received intravenous 2HPBCD twice a week for 6 weeks, followed by monthly infusion for 6months. Primary outcome measure was reduction of plasma (3β,5α,6β-trihydroxy-cholan-24-oyl) glycine
(TCG), a bile acid generated from cholesterol sequestered in lysosome.
Results: Three participants completed this protocol. A fourth patient received intravenous 2HPBCD under an
emergency investigational new drug study but later expired from her underlying condition. The three protocol
patients are living and have improved liver enzymes and TCG. No patient has experienced a drug-related adverse
event.
Conclusion: Intravenous 2HPBCD was tolerated in three infants with liver disease due to NPC.

1. Introduction
Niemann-Pick disease, type C (NPC) has an incidence of 1 in 120,000
live births. It results from pathogenic variant of either the NPC1 (~95%
of cases) or NPC2 genes [1]. The NPC1 protein is a cholesterol trafficking
protein, so the NPC1 gene mutation results in accumulation of unes
terified cholesterol and other lipids in lysosomes leading to disease
involving the central nervous system and peripheral tissues such as the
liver [1]. NPC has a phenotypic spectrum ranging from infantile death to
a chronic neurodegenerative disease in adulthood. Most commonly, it is
characterized by neurodegeneration in early childhood and death in
adolescence [1]. Individuals with NPC demonstrate progressive central
nervous system decline including inability to coordinate balance, gait,
and extremity movements. Liver disease in the newborn/infant period is
frequently observed. Some patients succumb to progressive liver

disease, but in many patients the liver disease improves resulting in
chronic liver disease [1].
There is currently no treatment for NPC in the United States, but
clinical trials are ongoing with 2-hydroxypropyl-beta-cyclodextrin
(2HPBCD). Here, we report our preliminary experience with intrave
nous 2HPBCD to treat the infantile liver disease in NPC patients. One
subject, Patient A, was treated under an emergency investigational new
drug (IND) study, and three have enrolled in a phase 1/2a, open-label,
multiple ascending dose trial. The study aims to evaluate whether
2HPBCD administered intravenously may be safe and effective in
treating liver disease in NPC infants.
2. Materials and methods
Studies were reviewed and approved by the Human Research
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Protection Office at Washington University in St. Louis School of Med
icine in St. Louis, Missouri. It was approved by the Federal Drug
Administration as an Investigational New Drug. All patients underwent
written, informed consent for the trial and gave permission for inclusion
in this report. 2HPBCD (Kleptose HPB) was formulated as VTS-270
(Mallinckrodt Pharmaceutical, Bedminster, NJ). Prior to the approval
of the open-label clinical trial, a patient with NPC and liver failure
presented to St. Louis Children's Hospital (SLCH), and was treated under
an emergency IND.

prothrombin time (PT).
2.6.2. Clinical chemistry
electrolytes, glucose, blood urea nitrogen (BUN), creatinine, AST,
ALT, gamma-glutamyl transferase (GGT), alkaline phosphatase, bili
rubin (direct and total), albumin, calcium, magnesium, phosphorus,
total protein, and creatine kinase (CK).
2.6.3. Urinalysis
protein, blood, leukocytes, glucose, ketones, bilirubin, urobilinogen,
pH, and specific gravity and microscopic analysis.
In Phase I, testing occurred at baseline, 2, 4 and 6 weeks. In Phase II,
testing occurred at baseline, 2, 4, and 6 months.
Patients also underwent additional research testing of NPC1 specific
markers including TCG (ref < 13.5 ng/mL), C-triol (ref <0.07 ng/mL), 7KC (ref <0.10 ng/mL), PPCS (ref <0.10 ng/mL) (Phase I: Baseline, 2, 4
and 6 weeks; Phase II: Baseline, 2, 4 and 6 months.).
Additional testing for the study included:
In Phase I: audiological evaluation, specifically, otoacoustic emis
sions (OAE) without sedation (baseline, 6 weeks)
Abdominal ultrasound (baseline, 6 weeks) Liver size was determined
by the liver's midclavicular longitudinal diameter. Organ volumes are
the product of three long axes (longitudinal, transverse and anteriorposterior).
In Phase II: abdominal ultrasound (6 months)
Subjects who demonstrated reduction either in TCG or serum bili
rubin (direct bilirubin or direct bilirubin:total bilirubin ratio) were
eligible to enter into the second Phase of the study, an open-label Phase
of six months duration in which IV 2HPBCD was administered monthly
for a total of six doses. Procedures during the second Phase included a
monthly intravenous line placement, physical assessment, blood draws
and urine collection during month 1, 2, 4, and 6, and monthly drug
administration.
Primary outcome measure is the efficacy of IV 2HPBCD to reduce
plasma levels of TCG. Secondary outcome measures include: effect of
drug on serum transaminases (ALT, AST) and reduction of liver and/or
spleen volumes.

2.1. Administration and dosing protocol
To be enrolled in the study, patients were required to be 0–6 months
of age, carry a diagnosis of NPC1 or NPC2, and have a hyper
bilirubinemia. VTS-270 was administered intravenously through a
peripherally inserted central catheter placed (PICC) place after admis
sion to the Neonatal Intensive Care Unit (NICU) at St. Louis Children's
Hospital. VTS-270 was provided as a 200 mg/mL solution and admin
istered at a rate of 250 mg/kg/h. Dosing for this phase one trial began at
500 mg/kg. The infusion rate was decreased in 25 mg/kg/h increments
to 175 mg/kg/h if required.
Infants remained in the NICU for doses 1 and 2, on standard NICU
continuous monitoring.
2.2. Doses 3–18
Interval between dosing was 4 ± 1 days. IV VTS-270 was adminis
tered via the central venous line at a rate of 250 mg/kg/h. Rate, vital
signs (temperature, heart rate, respiratory rate, supine blood pressure,
and SaO2) and standard neurological checks were conducted as for dose
1 and 2. These doses were given as an outpatient, within our Pediatric
Clinical Research Unit.
2.3. Modifications in the event of toxicity
If the subject did not tolerate the 500 mg/kg dose, the dose was to be
decreased to 250 mg/kg. If the subject did not tolerate the 1000 mg/kg
dose, the dose was to be decreased to 500 or 250 mg/kg.

3. Results

2.4. Emergency IND modifications
The subject treated under the eIND was initiated at 250 mg/kg, and
sequentially increased to 500 mg/kg, and 1000 mg/kg, when laboratory
and clinical status did not improve.

The study has enrolled three subjects, and none have withdrawn.
One additional patient was treated under an eIND for acute liver failure
before the study opened for enrollment. This patient, Patient A, expired
from her liver disease.

2.5. Assessment of efficacy

3.1. Patient A

Determination of efficacy was based upon biochemical response of
plasma biomarkers (e.g., cholestane-3β,5α,6β-triol (C-triol) [2], 7-keto
cholesterol (7-KC) [2], 3β,5α,6β-trihydroxy-cholan-24-oyl) glycine
(TCG) [3], and N-palmitoyl-O-phosphocholine-serine (PPCS)) [4];
serum aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) and total and direct bilirubin; and abdominal ultrasound to assess
changes in liver and spleen volumes.

A 38 3/7 weeks post menstrual age (PMA) female born at 2.63 kg
(Table 1) with birth history significant for intrauterine growth restric
tion, delayed prenatal care (21 weeks) due to lack of health insurance,
and family history of a “close” relative with a child who died at 2 months
of age due to unclear reasons including hepatic failure. Patient A pre
sented with cholestasis and hepatosplenomegaly (Fig. 1) at <1 week of
age. Coagulation studies were abnormal. Abdominal ultrasound
confirmed splenomegaly and revealed a coarse liver, loss of the uniform
smooth echotexture, with a cavernous hemangioma. Alpha fetoprotein
(AFP) was elevated at 77,000 ng/mL with repeat value of 92,000 (nl
<41,687 ng/mL). Sequencing of NPC1 revealed a likely pathogenic
variant designated as c. 3053 G > A;p.C1168Y [5] and a variant of un
certain significance (VUS) designated as c.1301C > G; p.P434R [6].
The Phase 1/2 clinical trial had not yet opened for enrollment, so a
single patient emergency treatment was pursued for this baby. At 6
weeks of life, she underwent her first infusion of 2HPBCD. At 6 weeks
old prior to initiation of the treatment, the child had hep
atosplenomegaly, end stage liver disease, ascites, direct hyper
bilirubinemia, elevated liver enzymes, hypoalbuminemia, and

2.6. Open-label clinical trial
For subjects in Phase I of the study, infants were treated twice weekly
for six weeks. After completion of Phase I, children were then evaluated
for eligibility to progress to Phase II of the study in which they were
treated once per month for six months.
Patients included in the study underwent the following laboratory
tests:
2.6.1. Hematology
complete blood count (CBC) with differential and platelet count, and
2
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Table 1
Demographics, genotype, and clinical summary of NPC patients.
Demographics
Sex
Race/Ethnicity
Estimated gestational age
Birth weight
Birth length
Occipitofrontal
circumference
Age at study enrollment

Patient A

Participant 1

Participant 2

Participant 3

Female
Southeast Asian
38 3/7 weeks
2630 g
47.1 cm
32 cm

Male
White/Hispanic
39 weeks
2899 g
50 cm
34 cm

Male
White/Hispanic
33 6/7 weeks
2495 g
45.5 cm
31.5 cm

Male
White
33 3/7 weeks
2125 g
45 cm
30 cm

Shortly after birth

4 months old

2 months old

5 months old

Genetic information
NPC1cDNA change

c.3503G > A

Protein change

p.C1168Y

Mutation types
Inheritance

Likely
pathogenic
Not tested

Method of detection

Cholestasis gene panel

Clinical information
Abdominal ascites
Neonatal jaundice
Hepatomegaly
Splenomegaly
Vertical supranuclear
gaze palsy

+
+
+
+
–

c.1301C >
G
p.P434R

c.2621A > T

c.3557G > A

c.2872C > T

c.451_452del

c.332dupG

c.1210C > T

p.D874V

p.R1186H

p.R958X

p.S151FfsX18

p.R404W

VUS

Pathogenic

Pathogenic

Pathogenic

Pathogenic

p.
A1108RfsX13
Pathogenic

MaternallyPaternallyinherited
inherited
Parental carrier screening, targeted
gene sequencing

MaternallyPaternallyinherited
inherited
Whole genome sequencing

Not tested

+ fetal
+
+
+
–

–
+
+
+
+

–
+
+
–
–

Likely
pathogenic

Cholestasis gene panel

Fig. 1. Biomarkers, liver function tests (LFTs) and bilirubin concentrations in Patient A. C-triol: cholestane-3β,5α,6β-triol C-triol. PPCS: N-palmitoyl-Ophosphocholineserine.

pancytopenia. Her multiple abdominal ultrasounds prior to treatment
revealed multiple and increasing hypoechoic liver lesions increasing,
hepatosplenomegaly, ascites, and edematous bowel. Doppler studies did
not document portal hypertension prior to treatment. She tolerated
doses at 250 mg/kg, 500 mg/kg, and 1000 mg/kg without adverse
events. The doses were escalated as she tolerated the medication, and
her systemic condition worsened. She completed 12 infusions of
2HPBCD. Her PPCS decreased from 3420 to 1610 (Fig. 1). Downtrending
of PPCS, which has been used as a marker for NPC severity, has been
previously been shown to decrease with IV 2HPBCD and potentially
indicates a reduction of lipid in the liver [2,7,8]. Unfortunately, the
patient expired prior to undergoing monthly infusions due to end stage
liver disease that was unrelated to drug administration (Fig. 1, Supple
mentary Table 1).

3.2. Study participant 1
The first study subject received a prenatal diagnosis of NPC1. Fetal
ascites was noted at the 24-week ultrasound. DNA extracted from am
niotic fluid revealed that the patient was compound heterozygous for
two pathogenic variants, one maternally inherited (c.2621A > T, p.
D874V) [9] and the other paternally inherited (c.3557G > A, p.
R1186H). The patient was born at 39 weeks (Table 1) and admitted to
the NICU post-delivery. Phototherapy was initiated for hyper
bilirubinemia. (Fig. 2a, Supplementary Table 2).
The study was first contacted when he was 4 months of age. Physical
examination showed hepatosplenomegaly. Abdominal ultrasound
revealed cirrhosis and a hyperechoic lesion within segment 4, which was
thought to represent a cholesterol deposit. AFP was elevated at 23,135
3
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Fig. 2. Biomarkers, liver function tests (LFTs) and bilirubin concentrations in clinical trial subjects. A) Study participant 1; B) Study participant 2; C) Study
participant 3. Gray shading indicates second phase of the study, when dosing frequency changed from twice weekly (approximately every four days) to once monthly.
TCG: 3β,5α,6β-trihydroxycholan-24-oyl glycine. Study participant 2 experienced an acute change in liver function studies at month 2 (dose 14) which corresponded
temporally with a viral infection. Scale of y-axis differs between Figs. 1 and 2.

ng/mL (nl 8-87 ng/mL). He was started on IV 2HPBCD per study pro
tocol at age 4 months. A repeat AFP level at 6 months demonstrated
downward trending levels to 1171 ng/mL. Direct bilirubin decreased to
0.3 mg/dL (nl 0.1–0.3) two weeks after his first infusion and remained
within normal limits after the 6-week infusion completing the first phase
of the protocol (Fig. 2, Supplementary Table 2). He met criteria to
transition to the second Phase of the study and was treated monthly with
IV 2HPBCD for six months. At the end of the study, his AST and ALT
improved but remained elevated. His bile acid marker was similarly
improved but elevated.
The liver size at the end of the study by ultrasound was 8.7 cm, which
was improved from initiation of the study. (Table 2) Finally, OAE
remained within normal limits for the duration of the study.

sequencing revealed that the patient was compound heterozygous for
two pathogenic variants in NPC1, one maternally inherited (c.2872C >
T, p.Arg958Ter) and the other paternally inherited (c.451_452del, p.
Ser151PhefsTer18)e.
The study was first contacted when he was 2 months old. This patient
initiated study treatment at age 2 months of age and completed Phase I
of the protocol receiving two infusions of IV 2HPBCD per week for 6
weeks. After Phase I his liver function studies showed improvement
(Fig. 2b, Supplementary Table 3). After completion of the monthly in
fusions, his AST remained somewhat elevated at 75 units/L (nl 10–60
units/L) and ALT 48 units/L (nl 5–50 units/L). His bile acid B was 101
ng/mL. His liver by ultrasound measured 8.10 cm which was improved
from baseline at the initiation of the study (Supplementary Table 5) The
participant's OAE remained unchanged for the duration of the study.

3.3. Study participant 2

3.4. Study participant 3

The second study participant was a male infant born at 33 6/7 weeks
gestational age. Pregnancy was complicated by preterm labor and
breech presentation. He was delivered by C-section with a birth weight
of 2.495 kg (Table 1). The patient was admitted to the NICU for three
weeks due to poor weight gain and persistent elevated bilirubin and liver
transaminases. (Fig. 2b., Supplementary Table 3) Whole genome

The third study participant was a 5-month-old boy born at 33 3/7
weeks post-menstrual age due to preterm labor. His birthweight was
2125 g. He developed jaundice in the NICU which provoked a workup.
Genetic testing showed two heterozygous variants of NPC1: c.3320dupG
(p.A1109RfsX13 and a c.1210C > T (p.R404W) that were classified as
4
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3.6. Adverse events

Table 2
Abdominal ultrasound reports.

Patients have not had adverse events related to the study drug.
Adverse events occurring during the study have included PICC line er
ythema, elevated transaminases, fever, cough, and viral exanthem.

Patient A
Spleen size
Liver size
Body weight
Body length

a

Baseline

End treatment

6.90 cm
7.10 cm
2.60 kg
51.5 cm

9.00 cm
10.00 cm
4.00 kg
54.0 cm

4. Discussion
Four patients with NPC1 have received IV 2HPBCD at our institution.
Three patients are alive and had improvement in TCG and their liver
function studies, and bilirubin levels during the course of study partic
ipation. Neonatal liver disease typically resolves in infants with NPC1
who survive the acute phase, so it is difficult to determine whether IV
2HPBCD impacted the natural disease course. This study was limited by
a lack of control group due to concerns at the time that this would be
practically and ethically challenging.
NPC1 encodes a large membrane glycoprotein, which localizes to the
late endosome [10]. NPC2 encodes a small soluble lysosomal protein
that binds cholesterol. Both proteins are found in the late endosomal/
lysosomal (LE/LY) system. NPC1 and NPC2 protein are thought to
facilitate egress of cholesterol from LE/LY to other parts of the cell [11].
This accumulation of cholesterol then results in glycosphingolipid
accumulation [12]. These mutations lead to impairment in processing
and utilizing cholesterol causing cholesterol storage and alterations of
sphingomyelin metabolism in extra neural tissues [1]. The result of
NPC1 and NPC2 mutations is that cholesterol does not exit the endocytic
pathway but accumulates within lysosomes.
This accumulation causes half of patients to experience prolonged
neonatal cholestatic icterus and progressive hepatosplenomegaly
[9,13]. In most cases, the icterus spontaneously improves, but the hep
atosplenomegaly may persist. Among 10% of patients, the icterus
quickly worsens, and the patients develop liver failure. These patients
typically die before the age of 6 months.12 We cannot yet predict which
patients will recover from their liver disease versus which patients will
progress to liver failure [9]. Of the patients who survive liver failure, all
eventually experience progressive and fatal neurologic disease [14].
Classic neurologic symptoms include cerebellar ataxia, dysarthria,
dysphagia, dementia, and vertical supranuclear gaze palsy [14].
A study using intrathecal 2HPBCD/VTS-270 administration for NPC1
patients found that monthly 2HPBCD in 14 patients with NPC had
decreased disease progression compared to matched natural history
cohorts.15 Seven patients experienced no progression or mild improve
ment, while all patients included in a natural history cohort progressed
over 18 months [15].
The natural history of NPC has been studied. On review of 52 NPC
patients, 34 (65%) had liver disease. In this study, 3 infants had a pro
gressive course during infancy which led to their demise, 4 had pro
gressive liver disease, while 15 had mild persistent liver disease [9].
Similarly, in another review of patients in the UK with NPC, 47 of 94
patients had neonatal presentation, 4 of these patients died before age 1
[5]. A study from the same group in 2015 found that the severe neonatal
onset form of NPC was most commonly associated with death from liver
disease in 3 of 6 patients.13 In a NPC database, 87/136 patients returned
a questionnaire, and 52% reported neonatal jaundice with splenomegaly
(35%), hepatomegaly (31%) and ascites (19%). In our cohort, patient A
had evidence of progressive liver disease, and died in infancy. While
PPCS decreased in this baby after treatment, all biomarkers remained
very high, and the child ultimately progressed to liver failure and death.
All three infants (patients 1–3) enrolled in our study have mild persistent
liver disease. None of these infants have evidence of progressive liver
disease. On the contrary, there was an improvement in cholestasis in all
three infants and hepatomegaly (liver size on ultrasound) in all three
infants enrolled in our study. In addition, there were no signs indicating
development of portal hypertension or ascites on ultrasound or duplex
studies. The clinical significance of the persistent liver disease in NPC is
usually overshadowed by the development of severe neurologic disease.

Study Subject 1: VTS-270-WU01
Spleen size
Spleen volume
Liver size
Body weight
Body length

Baseline

End phase 1

End phase 2

8.56 cm
88.4 cc
9.55 cm
6.97 kg
67.0 cm

9.00 cm
98.1 cc
9.60 cm
7.90 kg
69.8 cm

10.4 cm
177.2 cc
8.7 cm
11.6 kg
78.2 cm

Baseline

End phase 1

End phase 2

7.96 cm
84.2 cc
8.83 cm
3.33 kg
50.5 cm

8.40 cm
71.8 cc
8.70 cm
4.40 kg
54.5 cm

11.20 cm
127.0 cc
8.10 cm
8.60 kg
72.8 cm

Baseline

End phase 1

End phase 2

6.70 cm
67.0 cc
9.00 cm
5.78 kg
61.5 cm

7.10 cm
58.6 cc
8.30 cm
7.10 kg
62.4 cm

7.60 cm
69.2 cc
10.00 cm
9.20 kg
72.7 cm

Study Subject 2: VTS-270-WU02
Spleen size
Spleen volume
Liver size
Body weight
Body length

Study Subject 3: VTS-270-WU03
Spleen size
Spleen volume
Liver size
Body weight
Body length
a

Measured by abdominal MRI.

likely pathogenic. 7-KC was elevated at 1.446 nmol/mL (ref <0.10), Ctriol was elevated at 0.300 nmol/L (ref <0.07), and PPCS was within
normal limits at 0.010 nmol/mL (ref <0.10). The oxysterol profile is
consistent with a biochemical diagnosis of NPC.
The study was first contacted about this patient when he was 4
months old. He presented 1 month later (Fig. 2c, Supplementary
Table 4) and initiated the study drug at age 5 months. After Phase I his
lab values improved. His liver was 8.3 cm, which was decreased from
baseline 9.0 cm. After completion of the monthly infusions, his AST
remained somewhat elevated at 77 units/L (nl 10–60 units/L) and ALT
65 units/L (nl 5–50 units/L). His final bile acid B was 87.9. His liver by
ultrasound measured 10 cm (Supplementary Table 5). The participant's
OAE remained unchanged for the duration of the study.
3.5. Subjects not enrolled
Twelve additional children were pre-screened for enrollment. Four
children did not meet inclusion criteria: one was excluded based on age
(10 years old), and three were excluded because they did not have liver
disease. Two children received off-site drug via an eIND: one because the
study had not yet opened for enrollment, and one because the child was
too unstable to travel. Two children were in critical condition and suc
cumbed to their illness prior to traveling to our institution or receiving
treatment. Finally, four children contacted the study team, but after
conversations with the team, families opted not to participate in the
study. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic was a factor in the decision not to travel to St. Louis for the
study for two of these four potential participants.

5
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In the aforementioned study, liver disease did not correlate with the
onset of neurologic disease, which starts at mean of 4.5 years [16]. We
did see an increase in splenomegaly in all three infants in our study [17].
The exact mechanism of 2HPBCD's effect is unknown. One theory is
that 2HPBCD reaches the LE/LY system and can facilitate movement of
stored cholesterol. It is believed that 2HPBCD can replace NPC1 or NPC2
or it may complex with other proteins and cause cholesterol flux in other
ways, e.g. promoting autophagic flux [18]. In so doing, it may lead to
normalized trafficking and clearance of accumulated cholesterol and
glycosphingolipids [19–21].
Because NPC is a cholesterol storage disorder, it results in an accu
mulation of cholesterols. The most important plasma biomarkers for
NPC include oxysterols (C-triol and 7-KC), TCG, and PPCS, all of which
are significantly elevated in NPC. However, we do not know how any of
these markers change over time. Oxysterols are generated from choles
terol trapped in lysosome due to oxidative stress, and TGC is a metab
olite of C-triol. The biosynthesis of PPCs is unknown, and it is very likely
that its elevation is secondary to accumulation of cholesterol in lyso
some. Cholesterol is significantly elevated in liver in NPC disease, and
liver is a major organ to produce oxysterols and TCG. Clearance of
accumulated cholesterol in lysosome of liver by 2HPBCD leads to
decrease of these NPC biomarkers [4]. Finally, 3 beta, 5 alpha, 6 betatrihydroxycholanic acid (bile acid B) is a metabolite of oysterol
cholestane-3 beta,5 alpha,6 beta-triol (COT) and is elevated in NPC. Our
group developed the bile acid B screening as a more suitable way to
screen infants for possible NPC using dried blood spots [22]. This assay
is now being piloted as a newborn screen in NY State.
In summary, three patients have been enrolled in this open-label
Phase I/II clinical trial for infants with liver disease due to NPC. One
additional patient was treated with an emergency IND, but succumbed
to liver disease. No patient has had significant adverse events related to
the drug. At last follow up, all surviving patients had TCG, a marker of
cholesterol storage, improved from the initial visit. Liver transaminases
improved all subjects. Liver size decreased in all subjects. Additional
subject accrual and study are needed to determine whether neonatal
liver disease due to NPC may improve during treatment with 2HPBCD.
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